Mode
Text Size
Log in / Sign up
N/A N=39 Treatment

Clinical Characterization of an Investigational Frequent Replacement Daily Wear Silicone Hydrogel Sphere Contact Lens

Refractive Errors

Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Front Surface Wettability, by Category — 78; 0; 0; 0 eyes

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
LID021201 contact lenses (Device); OPTI-FREE multipurpose solution (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alcon Research
Primary completion
Feb 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Front Surface Wettability, by Category
78; 0; 0; 0; 0; 56

Summary

The primary objective of this study is to evaluate the overall clinical performance of an investigational silicone hydrogel contact lens over 7 days of daily wear.

Eligibility Criteria

Inclusion Criteria

  • Understand and sign an Informed Consent that has been approved by an Institutional Review Board.
  • Successful wear of spherical daily wear frequent replacement soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months.
  • Willing to stop wearing habitual contact lenses for the duration of study participation.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Any condition that contraindicates contact lens wear, as determined by the Investigator.
  • Any use of systemic or ocular medications that contraindicates contact lens wear, as determined by the Investigator.
  • History of refractive surgery or plan to have refractive surgery during the study.
  • Current or history of dry eye in either eye that, in the opinion of the Investigator, would preclude contact lens wear.
  • Wears habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04702984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search